ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
ImmunityBio, Inc.NASDAQ: IBRX
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow declines year over year
Q3 FY2026 financing cash flow of $53.03M fell 69.4% year over year, behind the -16.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 19.3% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Financing cash flow amounted to 353.3% of revenue in FY2025, down 1556.7 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -69.4% toward the trailing-twelve-month pace of -16.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 400.24M USD
- Year-over-year change
- +42.1%
- 4-year CAGR
- -5.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 400.24M | +42.1% |
| FY2024 | 2024-12-31 | 281.63M | -49.6% |
| FY2023 | 2023-12-31 | 558.34M | +139.0% |
| FY2022 | 2022-12-31 | 233.61M | -53.8% |
| FY2021 | 2021-12-31 | 505.44M | — |
Financing Cash Flow vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.8% is the 8th highest of 11, against a peer median of +131.9%.
- Financing cash flow amounts to 206.1% of revenue for IBRX, versus a peer median of 79.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.34B USD | +36966.7% | — | 132.1% | |
| LTM Sep 2026 | $376.3M USD | -16.8% | +19.7% | 206.1% | |
| LTM Sep 2026 | $286.08M USD | +15.9% | +16.5% | 75.5% | |
| LTM Mar 2026 | $165.71M USD | +3328.0% | -52.2% | 253.0% | |
| LTM Mar 2026 | €118.48M EUR | -17.9% | -8.9% | 317.7% | |
| LTM Sep 2026 | $115.15M USD | +822385.3% | — | 8.5% | |
| LTM Jun 2026 | €112.12M EUR | +142.6% | -67.0% | 4.2% | |
| LTM Mar 2026 | $37.29M USD | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $19.3M USD | -44.7% | -32.8% | 83.4% | |
| LTM Mar 2026 | $10.47M USD | +121.3% | -60.2% | 2.7% | |
| LTM Mar 2026 | $147K USD | +180.8% | -91.4% | — | |
| Peer median (excluding IBRX) | — | +131.9% | -42.5% | 79.4% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (346.79M) | (416.57M) | (583.85M) | (413.65M) | (351.47M) |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.18M | 40.18M | 49.16M | 34.43M | 36.81M |
| Change in Working Capital | (15.4M) | (16M) | 3.83M | (19.42M) | (54.33M) |
| Accounts Receivables | 0 | 0 | 0 | (2.36M) | (40.21M) |
| Inventory | 0 | 0 | 0 | (8.27M) | (6.33M) |
| Accounts Payables | 0 | 0 | (6.48M) | (3.17M) | (190K) |
| Other Working Capital | (15.4M) | (16M) | 10.3M | (5.62M) | (7.6M) |
| Other Non-Cash Items | 16.35M | 36.62M | 145.44M | (10.16M) | 48.53M |
| Operating Cash Flow | (274.42M) | (337.51M) | (366.76M) | (391.24M) | (304.94M) |
| Capital Expenditures | (33.56M) | (78.16M) | (30.58M) | (6.89M) | (3.85M) |
| Acquisitions (Net) | 0 | 0 | 0 | (1M) | 0 |
| Purchases of Investments | 0 | 0 | (10.36M) | (140.22M) | (241.37M) |
| Sales of Investments | 0 | 0 | 10.47M | 136.61M | 95.82M |
| Other Investing Activities | (51.32M) | 105.46M | 0 | (747K) | 0 |
| Investing Cash Flow | (84.89M) | 27.3M | (30.47M) | (12.25M) | (149.8M) |
| Debt Repayment | 338.5M | 174.07M | 451.39M | 96.89M | 1.72M |
| Common Stock Issued | 0 | 0 | 110.4M | 111.36M | 400.78M |
| Common Stock Repurchased | (4.06M) | (616K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 171.01M | 60.16M | (3.44M) | 73.38M | (2.27M) |
| Financing Cash Flow | 505.44M | 233.61M | 558.34M | 281.63M | 400.24M |
| Effect of Forex Changes | 48K | 284K | (292K) | (23K) | 15K |
| Net Change in Cash | 146.19M | (76.32M) | 160.82M | (121.88M) | (54.48M) |
| Free Cash Flow | (307.98M) | (415.67M) | (397.34M) | (398.12M) | (308.78M) |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.